暂无数据
暂无内容
暂无数据
暂无数据
暂无数据
快讯 | Adverum Biotechnologies Inc:瑞穗将目标价从40美元下调至22美元
Reuters24分钟前
Adverum Biotechnologies将在ASRS年度科学会议上介绍为期26周的LUNA第二阶段中期分析
Adverum Biotechnologies, Inc.(纳斯达克股票代码:ADVM)是一家开创使用基因疗法作为高度流行眼部疾病新护理标准的临床阶段公司,今天宣布,该公司
Benzinga04/25 16:40 (美东)
周二盘后交易时段,12只医疗保健股走势
在周二的盘后交易中,Gainers180生命科学(纳斯达克股票代码:ATNF)股价上涨7.4%,至2.04美元。他们已发行股票的市值为170万美元。ABVC 生物制药 (NAS)
Benzinga04/23 16:31 (美东)
今年,Adverum Biotechnologies(ADVM)的涨幅是否超过了其他医疗股?
Yahoo Finance04/23 09:40 (美东)
今年的医疗股是否落后于Adverum Biotechnologies(ADVM)?
Yahoo Finance04/04 09:40 (美东)
分析师对这些医疗保健股持中立态度:SAGE Therapeutics(SAGE)、Adverum Biotechnologies(ADV
TipRanks03/27 21:50 (美东)
QianmengYu楼主 : 我居然亏钱了。日了狗了。早知道把本金都掏出来了
QianmengYu : nice!
QianmengYu : drop to halt. Hmmm
QianmengYu楼主 : so strange. If insider knew data is so great, they won’t finance at 1.2 with almost 100% dilution, Private placement will get 50% shares thereafter, insider get somewhat. That’s more shares than they can dump to open market. what’s point to pump to 2.8? I don’t think in current US regulations, someone can take over a company simply just by private share issuing and collecting sufficient shares on open market (allowed in some countries). Let’s see.
暂无数据
暂无数据